Table 2 Correlation analysis of CA125 and HE4 with clinical pathological data
From: HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect
|  | Cases n = 130(%) | IH Detection (%) | Average Value | |||
|---|---|---|---|---|---|---|
CA125 | HE4 | Serum CA125 | Ascitic HE4 | Ascitic CA125 | ||
Age | ||||||
  ≤ 50 | 26(20.00) | 18(69.23) | 18(69.23) | 273.23 | 3153.48 | 952.93 |
 >50 | 104(80.00) | 88(84.62) | 88(84.62) | 568.07 | 2116.72 | 910.46 |
Chemotherapy | ||||||
 With | 54(41.54) | 46(85.19) | 46(85.19) | 354.71*** | 932.56*** | 1002.04 |
 Without | 76(58.46) | 60(78.95) | 60(78.95) | 618.8 | 3312.78 | 859.92 |
Histological type | ||||||
 Serous | 100(76.93) | 94(94.00) | 94(94.00) | 554.23 | 2133.79*** | 961.44 |
  LGSC | 3(3.00) | 1(1.06) | 1(1.06) | 612.50 | 2388.38 | 1146.59 |
  HGSC | 97(97.00)) | 93(98.94) | 93(98.94) | 552.43 | 2125.92*** | 955.71 |
 Mucinous | 10(7.69) | 2(10.00) | 2(10.00) | 27.34 | 2881.84 | 732.97 |
 Others | 20(15.38) | 10(50.00) | 10(50.00) | 524.34 | 2996.59 | 799.52 |
LN metastasis | ||||||
 With | 62(47.69) | 56(90.320) | 56(90.32) | 632.56 | 2220.1 | 910.17 |
 Without | 68(53.31) | 50(73.53) | 50(73.53) | 396.54* | 2418.87 | 926.96 |